Responses
Clinical/translational cancer immunotherapy
Original research
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
